Fig 5. Praziquantel treatment does not alter SmLy6A and SmLy6B IgG₁ age distribution profiles, but does decrease antigen-specific IgG₁ reactivity.

SmLy6A-, SmLy6B- and SmTAL1-specific IgG₁ were measured before and 9 weeks after praziquantel treatment in a cohort of infected males (n = 216). A) Age–associated profiles of SmLy6A-, B) SmLy6B-, and C) SmTAL1-specific IgG₁ responses pre- and post-praziquantel treatment. (D) Effect of praziquantel treatment on human IgG₁ responses to SmLy6A, (E) SmLy6B and (F) SmTAL1. IgG₁ levels for those individuals producing a detectable response (>mean+3xSD uninfected controls) to SmLy6A (n = 16), SmLy6B (n = 50) or SmTAL1 (n = 26) before treatment are shown and the median value is represented by a horizontal bar. P-values were calculated using a Wilcoxon signed-rank test comparing pre-treatment and post-treatment antibody levels.